25. A topical pharmaceutical composition comprising:
   a) umeclidinium present in an amount from about 0.5% to about 5% by weight;
   b) water in an amount from about 5% to about 25% by weight; and
   c) at least one water miscible organic solvent in an amount from about 70% to about 90% by weight, which is a mixture comprising diethylene glycol monoethyl ether and propylene glycol,

wherein all % are based on the total weight of the composition.

26. A method of reducing or preventing perspiration comprising applying to the skin of a human a therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof.

27. A method of treating hyperhidrosis in a human in need thereof, comprising applying to the skin of said human a therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof.

28. A method of treating or minimizing or preventing undesirable odors associated with human sweat glands and skin in a human in need thereof, comprising applying to the skin of said human a therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof.

29. A method for the prophylaxis or treatment of excessive sweating or hyperhidrosis comprising administering either sequentially or simultaneously, to a patient in need thereof, a therapeutically effective amount of a first therapeutic agent which is 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane and a pharmaceutically acceptable anion thereof (umeclidinium), and at least one other therapeutic agent.

30. The method according to claim 27 wherein the umeclidinium and the at least one other therapeutic agent are administered in the same pharmaceutical product.

31. A pharmaceutical composition for topical administration comprising a therapeutically effective amount of umeclidinium, and a pharmaceutically acceptable solvent, wherein the composition produces a maximum plasma level of umeclidinium at steady state of less than 1607 pcg/mL.

32. A pharmaceutical composition for topical administration comprising a therapeutically effective amount of umeclidinium, and a pharmaceutically acceptable solvent, wherein the composition produces an AUC(0-tau) at steady state of less than 2541 hr *pcg/mL.

33. A pharmaceutical composition for topical administration comprising a therapeutically effective amount of umeclidinium, and a pharmaceutically acceptable solvent, wherein the composition produces a maximum plasma level of umeclidinium less than 1607 pcg/mL, and an AUC(0-tau) at steady state of less than 2541 hr *pcg/mL.

25. A topical pharmaceutical composition comprising:

a) umeclidinium present in an amount from about 0.5% to about 5% by weight;

b) water in an amount from about 5% to about 25% by weight; and

c) at least one water miscible organic solvent in an amount from about 70% to about 90% by weight, which is a mixture comprising diethylene glycol monoethyl ether and propylene glycol,

wherein all % are based on the total weight of the composition.

26. A method of reducing or preventing perspiration comprising applying to the skin of a human a therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof.

27. A therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof for use in the treatment of hyperhidrosis in a human in need thereof, wherein the composition is to be applied to the skin of said human.

28. A therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof for use in the treatment or minimization or prevention of undesirable odors associated with human sweat glands and skin in a human in need thereof, wherein the composition is to be applied to the skin of said human.

29. A therapeutically effective amount of a first therapeutic agent which is 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane and a pharmaceutically acceptable anion thereof (umeclidinium), and at least one other therapeutic agent for use in the prophylaxation or treatment of excessive sweating or hyperhidrosis, wherein the aforementioned components are to be administered either sequentially or simultaneously to a patient in need thereof.

30. The components for use according to claim 29 wherein the umeclidinium and the at least one other therapeutic agent are to be administered in the same pharmaceutical product.

31. Use of a therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof in the manufacture of a medicament for the treatment of hyperhidrosis, which is to be applied to the skin of a human in need thereof.

32. Use of a therapeutically effective amount of a composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane, and a pharmaceutically acceptable anion thereof (umeclidinium), and a pharmaceutically acceptable carrier thereof in the manufacture of a medicament for the treatment or minimization or prevention of undesirable odors associated with human sweat glands and skin, which is to be applied to the skin of a human in need thereof.

33. Use of a therapeutically effective amount of a first therapeutic agent which is 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane and a pharmaceutically acceptable anion thereof (umeclidinium), and at least one other therapeutic agent in the manufacture of a medicament for the prophylaxation or treatment of excessive sweating or hyperhidrosis, wherein the aforementioned components are to be administered either sequentially or simultaneously to a patient in need thereof.

34. The use according to claim 33 wherein the umeclidinium and the at least one other therapeutic agent are to be administered in the same medicament.

35. A pharmaceutical composition for topical administration comprising a therapeutically effective amount of umeclidinium, and a pharmaceutically acceptable solvent, wherein the composition produces a maximum plasma level of umeclidinium at steady state of less than 1607 pcg/mL.

36. A pharmaceutical composition for topical administration comprising a therapeutically effective amount of umeclidinium, and a pharmaceutically acceptable solvent, wherein the composition produces an AUC(0-tau) at steady state of less than 2541 hr *pcg/mL.

37. A pharmaceutical composition for topical administration comprising a therapeutically effective amount of umeclidinium, and a pharmaceutically acceptable solvent, wherein the composition produces a maximum plasma level of umeclidinium less than 1607 pcg/mL, and an AUC(0-tau) at steady state of less than 2541 hr *pcg/mL.